Loading...
XMIL
LBM
Market cap210mUSD
Aug 29, Last price  
9.95EUR
Name

Labomar SpA

Chart & Performance

D1W1MN
XMIL:LBM chart
P/E
29.93
P/S
2.00
EPS
0.33
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
3.65%
Revenues
92m
+40.38%
41,876,00043,471,00056,568,00061,059,44865,412,04991,824,433
Net income
6m
-26.51%
4,144,0004,349,0005,017,0006,093,8838,360,3356,144,136
CFO
10m
+15.23%
9,598,0006,738,0008,072,0008,413,6158,724,73210,053,489
Dividend
May 15, 20230.1 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Labomar S.p.A., an Italian company established in 1998 and headquartered in Istrana, specializes in the global research, development, production, and commercialization of a wide range of health-focused products. Its market presence spans Italy, France, Poland, Spain, North America, and other international regions. The company's comprehensive product line includes food supplements addressing diverse therapeutic needs such as immune system support, digestive health, respiratory conditions (cough and cold), neurological wellness, oncology support, vision care, sports nutrition, dermatological health, 'inside beauty' applications, cardiovascular health, orthopedic issues, pediatrics, detoxification, and metabolic syndrome management. This segment also features essential vitamins, minerals, and antioxidants. Labomar further manufactures medical devices for use in gynecology, respiratory and gastrointestinal ailments, wound healing, metabolic disorders, proctology, detoxification, and oral wound care. Additionally, it provides foods for special medical purposes, catering to needs in gastroenterology, endocrinology, and dysphagia. Within its cosmetics division, the company develops products for internal beauty, skin cleansing, general skincare, haircare, oral wound care, sun protection, and specific dermatological conditions including acne rosacea, acne, atopic dermatitis, and bruises. Probiotic food supplements are also part of its offerings. Beyond its proprietary brands, Labomar extends its expertise through contract development and manufacturing services for other companies. Its products are available in various formats, including tablets, capsules, liquids, powders, and semi-solids. A significant commercial partnership with Bayer involves Labomar in the development and production of various pharmaceutical formulations in different flavors and forms.
IPO date
Oct 05, 2020
Employees
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT